Orange Book product · Generic (ANDA)
DEFERASIROX
DEFERASIROX
At a glance
Sep 08, 2025
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 08, 2025
9 mo ago
Today
Pharmaceutical detail
Active ingredient
DEFERASIROX
Strength
90MG
Dosage form
GRANULE
Route
ORAL
TE code
AB
Application
ANDA 215137
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DEFERASIROX
- 2017JADENU SPRINKLEBrand (NDA)
NDA 207968 · NOVARTIS
- 2015JADENUBrand (NDA)
NDA 206910 · NOVARTIS PHARMS CORP
- 2005EXJADEBrand (NDA)
NDA 021882 · NOVARTIS
- 2025DEFERASIROXGeneric (ANDA)
ANDA 211660 · JUBILANT GENERICS
- 2024DEFERASIROXGeneric (ANDA)
ANDA 209426 · TORRENT
- 2024DEFERASIROXGeneric (ANDA)
ANDA 206585 · PHARMOBEDIENT
- 2024DEFERASIROXGeneric (ANDA)
ANDA 213146 · PHARMOBEDIENT
- 2024DEFERASIROXGeneric (ANDA)
ANDA 211395 · PHARMOBEDIENT
- 2023DEFERASIROXGeneric (ANDA)
ANDA 214474 · AUROBINDO PHARMA LTD
- 2023DEFERASIROXGeneric (ANDA)
ANDA 216229 · ANNORA PHARMA
- 2022DEFERASIROXGeneric (ANDA)
ANDA 207124 · TEVA PHARMS USA
- 2022DEFERASIROXGeneric (ANDA)
ANDA 214650 · MSN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
